- Home
- DSGN vs CADL Comparison
DSGN vs CADL Comparison
Compare DSGN & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- CADL
- Stock Information
- Founded
- DSGN 2017
- CADL 1999
- Country
- DSGN United States
- CADL United States
- Employees
- DSGN N/A
- CADL N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- CADL Health Care
- Exchange
- DSGN Nasdaq
- CADL Nasdaq
- Market Cap
- DSGN 224.8M
- CADL 234.8M
- IPO Year
- DSGN 2021
- CADL 2021
- Fundamental
- Price
- DSGN $3.98
- CADL $5.60
- Analyst Decision
- DSGN Hold
- CADL Strong Buy
- Analyst Count
- DSGN 1
- CADL 4
- Target Price
- DSGN $4.00
- CADL $21.00
- AVG Volume (30 Days)
- DSGN 91.9K
- CADL 991.5K
- Earning Date
- DSGN 05-07-2025
- CADL 05-13-2025
- Dividend Yield
- DSGN N/A
- CADL N/A
- EPS Growth
- DSGN N/A
- CADL N/A
- EPS
- DSGN N/A
- CADL N/A
- Revenue
- DSGN N/A
- CADL N/A
- Revenue This Year
- DSGN N/A
- CADL N/A
- Revenue Next Year
- DSGN N/A
- CADL N/A
- P/E Ratio
- DSGN N/A
- CADL N/A
- Revenue Growth
- DSGN N/A
- CADL N/A
- 52 Week Low
- DSGN $2.60
- CADL $3.79
- 52 Week High
- DSGN $7.77
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- DSGN 53.86
- CADL 50.95
- Support Level
- DSGN $3.67
- CADL $5.37
- Resistance Level
- DSGN $4.13
- CADL $6.29
- Average True Range (ATR)
- DSGN 0.30
- CADL 0.40
- MACD
- DSGN 0.05
- CADL 0.06
- Stochastic Oscillator
- DSGN 85.78
- CADL 36.54
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.